Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial

NCT05686538 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

AML/MDS

Interventions

OTHER: iDLI

Sponsor

Rigshospitalet, Denmark